Dittmann K H, Dikomey E, Mayer C, Rodemann H P
Department of Radiotherapy, Eberhard-Karls-University, Tübingen, Germany.
Int J Radiat Biol. 2000 Feb;76(2):223-9. doi: 10.1080/095530000138871.
The radioprotective effect of the Bowman-Birk protease inhibitor (BBI) was previously shown to result from a TP53 dependent mechanism. Whether this effect involves specific DNA repair mechanisms is now tested.
Normal human fibroblasts were pre-treated with BBI before exposure to X-rays, UVB or to chemical agents (bleomycin, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), cisplatin). These agents were chosen because of their ability to induce different spectra of DNA damage. The radiometric agent bleomycin primarily induces double-strand breaks (dsb), which are repaired by recombination; MNNG results in alkylated bases which are repaired by base excision repair (BER); cisplatin results in DNA-crosslinks which are repaired mainly by nucleotide excision repair (NER); and finally UVB generates thymine dimers and thymine-cytosine-6-4 products which are also repaired by NER. Cell survival was analysed by colony formation assay and DNA dsb by constant field gel electrophoresis. The combined effect of BBI and X-rays was also tested for XP-fibroblasts, which are defective in NER.
For normal human fibroblasts the radioprotective effect of BBI was clearly found by using a delayed plating procedure. The radioprotective effect was found to be unrelated to an altered induction or repair of radiation-induced DNA dsb. Pretreatment with BBI did not affect cell killing after exposure to bleomycin or MNNG, but resulted in a significant protection of cells exposed to cisplatin or UVB. These results indicate that pre-treatment with BBI did not alter recombination repair or BER, but was able to modify NER. The latter finding was supported by the observation made for XP-cells, where pretreatment with BBI failed to result in radioprotection after exposure to ionizing radiation.
On the basis of these data it is proposed that the radioprotective effect of BBI is the result of an improved nucleotide excision repair mechanism.
先前已表明鲍曼-伯克蛋白酶抑制剂(BBI)的辐射防护作用是由一种依赖TP53的机制产生的。现在测试这种作用是否涉及特定的DNA修复机制。
正常人成纤维细胞在暴露于X射线、紫外线B(UVB)或化学试剂(博来霉素、N-甲基-N'-硝基-N-亚硝基胍(MNNG)、顺铂)之前先用BBI进行预处理。选择这些试剂是因为它们能够诱导不同类型的DNA损伤。放射性试剂博来霉素主要诱导双链断裂(dsb),通过重组进行修复;MNNG导致碱基烷基化,通过碱基切除修复(BER)进行修复;顺铂导致DNA交联,主要通过核苷酸切除修复(NER)进行修复;最后,UVB产生胸腺嘧啶二聚体和胸腺嘧啶-胞嘧啶-6-4产物,也通过NER进行修复。通过集落形成试验分析细胞存活率,通过恒定电场凝胶电泳分析DNA双链断裂。还测试了BBI与X射线对核苷酸切除修复有缺陷的着色性干皮病(XP)成纤维细胞的联合作用。
对于正常人成纤维细胞,通过使用延迟接种程序清楚地发现了BBI的辐射防护作用。发现辐射防护作用与辐射诱导的DNA双链断裂的诱导或修复改变无关。用BBI预处理在暴露于博来霉素或MNNG后不影响细胞杀伤,但对暴露于顺铂或UVB的细胞有显著保护作用。这些结果表明,用BBI预处理不会改变重组修复或碱基切除修复,但能够改变核苷酸切除修复。对XP细胞的观察支持了后一发现,即对XP细胞用BBI预处理在暴露于电离辐射后未能产生辐射防护作用。
基于这些数据,提出BBI的辐射防护作用是核苷酸切除修复机制改善的结果。